Jan 05, 2017 12:01 pm UTC| Business
SAN DIEGO, Jan. 05, 2017 -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced...
Microbot Medical Inc. Announces $3.5 Million Registered Direct Offering
Jan 05, 2017 12:01 pm UTC| Business
HINGHAM, Mass., Jan. 05, 2017 -- Microbot Medical Inc. (NasdaqCM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that it...
Microbot Medical Inc. Announces $3.5 Million Registered Direct Offering
Jan 05, 2017 12:01 pm UTC| Business
HINGHAM, Mass., Jan. 05, 2017 -- Microbot Medical Inc. (NasdaqCM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that it...
The Carlyle Group Completes Acquisition of Claritas from Nielsen
Jan 05, 2017 12:00 pm UTC| Business
NEW YORK, Jan. 05, 2017 -- Global alternative asset manager The Carlyle Group (NASDAQ:CG), in partnership with the Indian Hill Group, has acquired Claritas from Nielsen (NYSE:NLSN). The Indian Hill Group is a small team...
Immunomedics Announces Investor R&D Day on January 18, 2017
Jan 05, 2017 12:00 pm UTC| Business
-- Presentation to Include New IMMU-132 Data and Latest Data on Other Programs -- MORRIS PLAINS, N.J., Jan. 05, 2017 -- Immunomedics, Inc. (NASDAQ:IMMU) today announced that it will hold an Investor RD Day to present...
Jan 05, 2017 12:00 pm UTC| Business
WESTPORT, Conn., Jan. 05, 2017 -- REX Shares, LLC (REX) today announced its short volatility fund, the REX VolMAXX Short VIX Weekly Futures Strategy ETF (VMIN), achieved a total return of +81.04% (NAV) from its launch...
Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors
Jan 05, 2017 12:00 pm UTC| Business
WALTHAM, Mass., Jan. 05, 2017 -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer...